MoonLake Immunotherapeutics (MLTX)
Market Price (12/29/2025): $13.82 | Market Cap: $875.8 MilSector: Health Care | Industry: Biotechnology
MoonLake Immunotherapeutics (MLTX)
Market Price (12/29/2025): $13.82Market Cap: $875.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% | Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -34% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -229 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% | ||
| High stock price volatilityVol 12M is 108% | ||
| Key risksMLTX key risks include [1] regulatory uncertainty for its lead drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -34% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -229 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% |
| High stock price volatilityVol 12M is 108% |
| Key risksMLTX key risks include [1] regulatory uncertainty for its lead drug, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Disappointing Phase 3 Clinical Trial Results: MoonLake Immunotherapeutics' lead drug candidate, sonelokimab, failed to meet its primary endpoint in the pivotal Phase 3 VELA-2 study for moderate-to-severe hidradenitis suppurativa (HS) around September 29, 2025. This outcome significantly undermined confidence in one of the company's most promising assets.
2. Higher-Than-Expected Placebo Response: The VELA-2 trial's failure to achieve statistical significance was attributed to a higher-than-expected placebo response rate, which cast doubt on sonelokimab's clinical efficacy and its ability to differentiate itself from competitors.
Show more
Stock Movement Drivers
Fundamental Drivers
The -77.7% change in MLTX stock from 9/28/2025 to 12/28/2025 was primarily driven by a -0.1% change in the company's Shares Outstanding (Mil).| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 61.99 | 13.83 | -77.69% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 63.28 | 63.37 | -0.14% |
| Cumulative Contribution | � |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| MLTX | -77.7% | |
| Market (SPY) | 4.3% | 4.6% |
| Sector (XLV) | 15.2% | 19.0% |
Fundamental Drivers
The -70.9% change in MLTX stock from 6/29/2025 to 12/28/2025 was primarily driven by a -0.2% change in the company's Shares Outstanding (Mil).| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 47.52 | 13.83 | -70.90% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 63.23 | 63.37 | -0.22% |
| Cumulative Contribution | � |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| MLTX | -70.9% | |
| Market (SPY) | 12.6% | 1.3% |
| Sector (XLV) | 17.0% | 7.7% |
Fundamental Drivers
The -75.0% change in MLTX stock from 12/28/2024 to 12/28/2025 was primarily driven by a -0.8% change in the company's Shares Outstanding (Mil).| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 55.37 | 13.83 | -75.02% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 62.90 | 63.37 | -0.75% |
| Cumulative Contribution | � |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| MLTX | -75.0% | |
| Market (SPY) | 17.0% | 11.5% |
| Sector (XLV) | 13.8% | 12.6% |
Fundamental Drivers
The 32.5% change in MLTX stock from 12/29/2022 to 12/28/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 10.44 | 13.83 | 32.47% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | � | 0.00 | � |
| P/S Multiple | � | ∞ | � |
| Shares Outstanding (Mil) | 36.93 | 63.37 | -71.62% |
| Cumulative Contribution | � |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| MLTX | -77.1% | |
| Market (SPY) | 48.4% | 14.9% |
| Sector (XLV) | 17.8% | 14.6% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MLTX Return | 8% | -13% | 6% | 475% | -10% | -74% | 32% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| MLTX Win Rate | 67% | 25% | 67% | 58% | 42% | 58% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| MLTX Max Drawdown | -3% | -13% | -53% | 0% | -36% | -88% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | MLTX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -63.6% | -25.4% |
| % Gain to Breakeven | 174.6% | 34.1% |
| Time to Breakeven | 267 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -5.8% | -33.9% |
| % Gain to Breakeven | 6.2% | 51.3% |
| Time to Breakeven | 34 days | 148 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
MoonLake Immunotherapeutics's stock fell -63.6% during the 2022 Inflation Shock from a high on 4/7/2022. A -63.6% loss requires a 174.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
- The Eli Lilly or AbbVie of highly specialized inflammatory disease drugs.
- A Moderna for autoimmune and inflammatory disease therapies, pioneering a new drug class.
AI Analysis | Feedback
- Sonelokimab: An investigational anti-IL-17A/F nanobody currently in clinical development for inflammatory diseases such as Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), and Axial Spondyloarthritis (AxSpA).
AI Analysis | Feedback
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing novel nanobody treatments for inflammatory diseases. As a company in the research and development phase, its primary product candidate, sonelokimab, is still undergoing clinical trials and has not yet received regulatory approval for commercial sale.
Therefore, MoonLake Immunotherapeutics does not currently have major customers in the traditional sense of selling products or services to other companies or individuals. The company's focus is on clinical development, and its revenue sources typically come from:
- Investments from venture capital firms and public market investors.
- Potential upfront payments from licensing or collaboration agreements with larger pharmaceutical companies, should it choose to partner for further development or commercialization upon approval.
Currently, there are no commercial sales to specific customer companies or categories of individual customers to report.
AI Analysis | Feedback
MoonLake Immunotherapeutics (MLTX) has identified the following major supplier:
- Lonza Group AG (SWX: LONN)
AI Analysis | Feedback
Jorge Santos da Silva – Chief Executive Officer
Jorge Santos da Silva is the co-founder and Chief Executive Officer of MoonLake Immunotherapeutics. He co-founded MoonLake AG in 2021 and served as its CEO before its merger with MLTX in April 2022, when he assumed the CEO role for the combined entity. He successfully guided MoonLake through its public listing on NASDAQ in 2022. Prior to MoonLake, Dr. Santos da Silva spent nearly 15 years as a Senior Partner at McKinsey & Company, where he led the Pharmaceutical & Medical Products Practice and the Biotech and Biosimilars groups. His consulting work involved advising numerous pharmaceutical and biotechnology companies on corporate strategy, business development, mergers and acquisitions, and commercialization. He holds a Ph.D. in Neuroscience and has a decade of experience in academic research.
Matthias Bodenstedt – Chief Financial Officer
Matthias Bodenstedt has served as the Chief Financial Officer of MoonLake Immunotherapeutics since July 2021. Before joining MoonLake, he was a Partner at McKinsey & Company from September 2015 to June 2021. At McKinsey, Mr. Bodenstedt provided extensive advisory services to a diverse range of biopharmaceutical clients, from early-stage biotechs to large global pharmaceutical companies, focusing on finance, commercial strategy, financing, mergers and acquisitions (M&A), and business development. MoonLake Immunotherapeutics was founded in 2021 with Series A financing led by BVF Partners LP, indicating his involvement with a company backed by a private equity firm from its early stages.
Kristian Reich – Chief Scientific Officer
Dr. Kristian Reich is a co-founder and the Chief Scientific Officer of MoonLake Immunotherapeutics. He is recognized globally as a key opinion leader and clinical expert in dermatology and immunology, with over 25 years of experience in the field. Dr. Reich has served as a principal investigator for numerous major biologic development programs, including for Merck's psoriasis program. His previous roles include Managing Partner at Dermatologikum Hamburg GmbH and Professor & Vice Director of the Dermatology Department at the University of Gottingen. He also serves on the Board of Directors for derma2go AG, Dermagnostix GmbH, and Proderma Foundation.
Arnout Ploos van Amstel – Chief Operating Officer
Arnout Ploos van Amstel is a co-founder and the Chief Operating Officer of MoonLake Immunotherapeutics. He brings over 25 years of experience as a global executive leader within the biopharma industry, including a tenure at Novartis.
Oliver Daltrop – Chief Technical Officer
Oliver Daltrop serves as the Chief Technical Officer at MoonLake Immunotherapeutics.
AI Analysis | Feedback
Key Risks to MoonLake Immunotherapeutics (MLTX)
The key risks to MoonLake Immunotherapeutics' business are primarily centered around clinical development, regulatory hurdles, shareholder litigation, and intense market competition.
1. Clinical Trial Setbacks and Regulatory Uncertainty
The most significant risk stems from the disappointing Phase 3 results for sonelokimab (SLK), the company's lead drug candidate, in hidradenitis suppurativa (HS). One of its two pivotal Phase 3 trials (VELA-2) narrowly missed its primary endpoint due to a higher-than-expected placebo response. This outcome has led to analyst skepticism regarding a swift regulatory clearance and has significantly reduced sales projections for the drug in HS. The company faces an upcoming FDA Type B meeting to discuss the adequacy of its current clinical package, which represents a critical regulatory milestone and a source of uncertainty.
2. Shareholder Litigation and Management Credibility
Following the Phase 3 setbacks, MoonLake Immunotherapeutics is facing multiple securities class action lawsuits. These lawsuits allege that the company misled investors about the efficacy of SLK and the purported advantages of its Nanobody structure compared to existing treatments, specifically the FDA-approved drug BIMZELX, which targets the same molecules. This litigation introduces risks related to potential settlement obligations and could undermine management credibility.
3. Intense Competition
Even if sonelokimab were to receive regulatory approval, it would enter a highly competitive landscape. The drug faces "intense competition" from "well-established IL-17 inhibitors" such as Cosentyx and the directly competing BIMZELX in large markets like hidradenitis suppurativa and psoriasis. Analysts have described sonelokimab's clinical data as "undifferentiated" compared to existing treatments, potentially limiting its market share and commercial success.
AI Analysis | Feedback
The most clear emerging threat to MoonLake Immunotherapeutics (MLTX) is the recent approval and market launch of UCB's bimekizumab (Bimzelx) for Hidradenitis Suppurativa (HS). Both MLTX's lead asset, sonelokimab, and UCB's bimekizumab are potent and selective inhibitors of both IL-17A and IL-17F. HS is the lead indication for sonelokimab, currently in Phase 3 trials. UCB's bimekizumab, with its very similar mechanism of action, received FDA approval for HS in October 2023. This provides a significant first-mover advantage to UCB and establishes a direct competitor with an analogous drug profile in MLTX's primary target market before sonelokimab has completed its pivotal studies and can seek regulatory approval.
AI Analysis | Feedback
MoonLake Immunotherapeutics (MLTX) is focused on developing sonelokimab, a Nanobody® therapy, for several inflammatory diseases. The addressable markets for their main products are as follows:- Hidradenitis Suppurativa (HS): The global addressable market for Hidradenitis Suppurativa is projected to reach approximately $15 billion by 2035.
- Psoriatic Arthritis (PsA): The global addressable market for Psoriatic Arthritis treatment is projected to reach approximately $25.89 billion by 2034.
- Axial Spondyloarthritis (axSpA): The global addressable market for Axial Spondyloarthritis is expected to reach approximately $10.8 billion by 2033.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for MoonLake Immunotherapeutics (MLTX) over the next 2-3 years:- Commercial Launch of Sonelokimab for Adult Hidradenitis Suppurativa (HS): MoonLake's lead product candidate, sonelokimab, is a novel Nanobody® therapy being developed for inflammatory diseases. The company is on track for a Biologic License Application (BLA) submission in mid-2026 for sonelokimab in adult Hidradenitis Suppurativa (HS), with potential FDA approval expected in 2026. This would mark MoonLake's first commercial product and is anticipated to be a significant driver of initial revenue growth.
- Expansion of Sonelokimab to Additional Indications: Beyond adult HS, MoonLake is actively pursuing clinical trials for sonelokimab across multiple other high-value inflammatory and dermatological conditions. These include psoriatic arthritis (PsA), adolescent HS, palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA). Successful progression and eventual regulatory approvals for these additional indications are expected to significantly broaden the addressable market for sonelokimab and fuel sustained revenue growth within the 2-3 year timeframe and beyond.
- Potential "Best-in-Class" Profile of Sonelokimab: Sonelokimab's Nanobody® technology offers potential advantages over traditional antibodies, such as enhanced tissue penetration and optimized inhibition of the IL-17A/A, IL-17A/F, and IL-17F/F dimers, which are central drivers of inflammatory disease. Positive clinical trial results have suggested sonelokimab's potential to be a "best-in-class" treatment for certain indications like HS. If this perception translates into strong clinical adoption upon commercialization, it could lead to rapid market penetration and a substantial share in its target markets, driving significant revenue.
AI Analysis | Feedback
Share Issuance
- MoonLake Immunotherapeutics priced an underwritten offering of 7,142,857 Class A ordinary shares at $10.50 per share on November 5, 2025, expecting to generate gross proceeds of approximately $75 million.
- The offering, which was anticipated to close around November 6, 2025, is being made by MoonLake itself under a shelf registration statement that became effective on September 11, 2023.
- The net proceeds from this offering are intended to fund the research and development of sonelokimab, the company's lead candidate, and for general corporate purposes.
Inbound Investments
- MoonLake Immunotherapeutics drew an initial $75 million under a $500 million credit facility, which is reflected as long-term debt on its balance sheet.
Capital Expenditures
- MoonLake Immunotherapeutics reported quarterly capital expenditures of $35,000 for March 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MLTX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for MoonLake Immunotherapeutics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Price Behavior
| Market Price | $13.83 | |
| Market Cap ($ Bil) | 0.9 | |
| First Trading Date | 10/20/2020 | |
| Distance from 52W High | -77.7% | |
| 50 Days | 200 Days | |
| DMA Price | $12.29 | $35.40 |
| DMA Trend | down | down |
| Distance from DMA | 12.5% | -60.9% |
| 3M | 1YR | |
| Volatility | 75.1% | 109.2% |
| Downside Capture | -94.65 | 72.20 |
| Upside Capture | -777.59 | -76.94 |
| Correlation (SPY) | -0.6% | 11.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.36 | 0.05 | -0.23 | 0.27 | 0.69 | 0.73 |
| Up Beta | -2.30 | 0.14 | 4.57 | 2.60 | 0.93 | 0.84 |
| Down Beta | 3.27 | -0.13 | -0.86 | -1.49 | 0.41 | 0.82 |
| Up Capture | 542% | 310% | -334% | -132% | -31% | 15% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 14 | 26 | 38 | 70 | 129 | 394 |
| Down Capture | 40% | -207% | -173% | -33% | 76% | 65% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 6 | 16 | 25 | 53 | 117 | 349 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of MLTX With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| MLTX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -73.5% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 108.3% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.19 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 12.8% | 11.6% | 0.5% | 5.7% | 9.8% | 1.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of MLTX With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| MLTX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 5.0% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 89.1% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.68 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 11.4% | 11.9% | 0.3% | -1.9% | 12.6% | 4.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of MLTX With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| MLTX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 5.5% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 87.9% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.68 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 11.1% | 11.8% | 0.3% | -1.8% | 12.5% | 4.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | 4.5% | 16.0% | 47.1% |
| 8/10/2023 | 0.6% | 5.9% | -5.7% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 1 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 2.5% | 10.9% | 47.1% |
| Median Negative | -5.7% | ||
| Max Positive | 4.5% | 16.0% | 47.1% |
| Max Negative | -5.7% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/05/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/12/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 02/26/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/07/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/07/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/29/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/14/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/10/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/11/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/20/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/14/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/12/2022 | 10-Q (06/30/2022) |
| 12/31/2021 | 03/04/2022 | DEFR14A (12/31/2021) |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.